Lukas C. Amler

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

David A. Eberhard, Bruce E. Johnson, Lukas C. Amler et al. · Journal of Clinical Oncology · 2005 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

David R. Gandara, Sarah Paul, Marcin Kowanetz et al. · Nature Medicine · 2018 · 1.2K citations

Medicine, Oncology, Pharmacology +16

Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts

Yudi Pawitan, Judith Bjöhle, Lukas C. Amler et al. · Breast Cancer Research · 2005 · 834 citations · Full text

Medicine, Cancer Biology, Oncology +17

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja et al. · Journal of Clinical Oncology · 2010 · 764 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL

Klaus W. Wagner, Elizabeth A. Punnoose, Thomas Januario et al. · Nature Medicine · 2007 · 603 citations

Life Sciences, Cell Biology, Oncology +16